Literature DB >> 11801521

Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne).

N Mandal, I H Chisholm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11801521      PMCID： PMC1770961          DOI： 10.1136/bjo.86.1.118

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  7 in total

1.  Age related macular degeneration. New hope for a common problem comes from photodynamic therapy.

Authors:  N M Bressler
Journal:  BMJ       Date:  2000-12-09

2.  Treatment of age-related macular degeneration.

Authors: 
Journal:  Clin Eye Vis Care       Date:  2000-03-01

3.  Use of eye care services among the 1991 Medicare population.

Authors:  L B Ellwein; V Friedlin; A M McBean; P P Lee
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

4.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

Review 5.  Laser treatments with verteporfin therapy and its potential impact on retinal practices.

Authors:  R R Margherio; A R Margherio; M E DeSantis
Journal:  Retina       Date:  2000       Impact factor: 4.256

6.  A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.

Authors:  M Sickenberg; U Schmidt-Erfurth; J W Miller; C J Pournaras; L Zografos; B Piguet; G Donati; H Laqua; I Barbazetto; E S Gragoudas; A M Lane; R Birngruber; H van den Bergh; H A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler
Journal:  Arch Ophthalmol       Date:  2000-03

7.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02
  7 in total
  4 in total

1.  Age-related maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions.

Authors:  Daniel E Weeks; Yvette P Conley; Hui-Ju Tsai; Tammy S Mah; Silke Schmidt; Eric A Postel; Anita Agarwal; Jonathan L Haines; Margaret A Pericak-Vance; Philip J Rosenfeld; T Otis Paul; Andrew W Eller; Lawrence S Morse; J P Dailey; Robert E Ferrell; Michael B Gorin
Journal:  Am J Hum Genet       Date:  2004-05-27       Impact factor: 11.025

2.  Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration.

Authors:  L Arias; O Pujol; J Berniell; M Rubio; G Roca; L Castillo; E Acebes
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

3.  Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6.

Authors:  Hyoung J Koh; Kenichiro Bessho; Lingyun Cheng; Dirk-Uwe Bartsch; Terence R Jones; Germain Bergeron-Lynn; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-02       Impact factor: 4.799

4.  Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization.

Authors:  Ji Hun Song; Ka Young Moon; Sung Chul Lee; Sung Soo Kim
Journal:  Int J Mol Sci       Date:  2020-04-18       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.